Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29624780 | 0.98 | KDM4E (0.34) | CYP4F2CYP4A11DGAT1ALDH1A1POLB | |
| SCHEMBL2477744 | 0.85 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1ALDH1A1POLB | |
| SCHEMBL23928775 | 0.79 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL2046 | 0.79 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1KDM4ELMNA | |
| SCHEMBL7438928 | 0.79 | CYP4F2 (0.46) | CYP4F2CYP4A11KDM4ELMNA | |
| SCHEMBL5000217 | 0.78 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1ALDH1A1POLB | |
| SCHEMBL2204111 | 0.78 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1ALDH1A1POLB | |
| SCHEMBL8487930 | 0.77 | DGAT1 (0.40) | CYP4F2CYP4A11DGAT1KDM4E | |
| Hydrochloric Acid SCHEMBL719464 | 0.77 | CYP4F2 (0.53) | CYP4F2CYP4A11ALDH1A1POLBKDM4E | |
| SCHEMBL17617116 | 0.76 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-101511836-A | Fused pyrimido compounds | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | CYP4F2 35/4885CYP4A11 11/4885DGAT1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.